First line and salvage therapy with total therapy 3-based treatment for multiple myeloma--An extended single center experience

Eli Muchtar, Ron Ram, Pia Raanani, Moshe Yeshurun, Nino Oniashvili, Ofer Shpilberg, Hila Magen

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Total therapy 3 is an intensified protocol for multiple myeloma (MM). The "real life" outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n=. 49; progressive MM, n=. 32), most of which had high-risk parameters. Overall response rate following (V)DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V)DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients.

Original languageEnglish
Pages (from-to)1401-1406
Number of pages6
JournalLeukemia Research
Volume38
Issue number12
DOIs
StatePublished - 1 Dec 2014
Externally publishedYes

Keywords

  • (V)DT-PACE
  • Bone disease
  • High dose therapy
  • High risk
  • Multiple myeloma
  • Total therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'First line and salvage therapy with total therapy 3-based treatment for multiple myeloma--An extended single center experience'. Together they form a unique fingerprint.

Cite this